BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scott FI, Lichtenstein GR. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017. Curr Treat Options Gastroenterol 2018;16:147-64. [PMID: 29492747 DOI: 10.1007/s11938-018-0177-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Patil SA, Bhat S, Limdi JK, Farraye FA, Cross RK. The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease. Inflamm Bowel Dis 2022;28:1915-23. [PMID: 35353189 DOI: 10.1093/ibd/izac048] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bartoška P, Paluch Z. Treatment of Crohn's disease. Gazz Med Ital - Arch Sci Med 2022;181. [DOI: 10.23736/s0393-3660.22.04819-7] [Reference Citation Analysis]
3 Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. Drugs 2021;81:1881-96. [PMID: 34596876 DOI: 10.1007/s40265-021-01601-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
4 Bernasko N, Clarke K. Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers? Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab004] [Reference Citation Analysis]
5 Wang H, Hu Y. CircRNA malignant fibrous histiocytoma amplified Sequence 1 (MFHAS1) reduced inflammatory responses in a Colitis Model via SIRT1/NF-κB. Food Sci Technol 2021;41:504-13. [DOI: 10.1590/fst.29220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Armuzzi A, Bouhnik Y, Cummings F, Bettey M, Pieper B, Kang T. Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. Dig Liver Dis 2020;52:1259-65. [PMID: 32601035 DOI: 10.1016/j.dld.2020.06.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
7 Scott FI. Infliximab Versus Biosimilars for IBD: Is It Better to Fight Than Switch? Dig Dis Sci 2020;65:2158-60. [PMID: 32338328 DOI: 10.1007/s10620-020-06283-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis 2020;14:575-87. [PMID: 31901085 DOI: 10.1093/ecco-jcc/jjz212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Wook Hong S, Kim YG, Ye BD. An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases. Immunotherapy 2020;12:609-23. [PMID: 32517574 DOI: 10.2217/imt-2020-0086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RWL; Asia-Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. J Gastroenterol Hepatol 2019;34:1296-315. [PMID: 30848854 DOI: 10.1111/jgh.14648] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
11 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 16.0] [Reference Citation Analysis]
12 Scott FI, Rubin DT, Kugathasan S, Bousvaros A, Elson CO, Newberry RD, Melmed GY, Pekow J, Fleshman JW, Boyle BM, Mahadevan U, Cannon LM, Long MD, Cross RK, Ha CY, Lasch KL, Robinson AM, Rafferty JF, Lee JJ, Dahl KDC, Weaver A, Shtraizent N, Honig G, Hurtado-Lorenzo A, Heller CA. Challenges in IBD Research: Pragmatic Clinical Research. Inflamm Bowel Dis 2019;25:S40-7. [PMID: 31095704 DOI: 10.1093/ibd/izz085] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
13 Shi HY, Ng SC. The state of the art on treatment of Crohn's disease. J Gastroenterol. 2018;53:989-998. [PMID: 29980848 DOI: 10.1007/s00535-018-1479-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]